Trevena, Inc. (TRVN) Company Profile
Trevena Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops and intends to commercialize therapeutics that use an approach to target G protein coupled receptors (GPCRs). Using its product platform, the Company has identified and advanced three differentiated product candidates: Oliceridine (TRV130), TRV027 and TRV250. Its TRV130 is a Mu-receptor G protein Pathway Selective (Mu-GPS) modulator that activates G protein. Its TRV250 is a small molecule G protein biased ligand of the d-opioid receptor in preclinical development. Its TRV734 is a small molecule Mu-GPS that it has discovered and has developed through Phase I as a first-line, orally administered compound for the treatment of moderate to severe acute and chronic pain. Its TRV027 is a peptide b-arrestin biased ligand that targets the angiotensin II type 1 receptor (AT1R). In addition to these three product candidates, the Company has identified and has completed the Phase I program for TRV734.
News about TRVN
What I Learned About Bitcoin Could Make You A Fortune...
When I was first asked to write a book about bitcoin, the price was hovering at about $3,000. As part of my research, I bought a little. By the time the book was finished, which was really only a matter of weeks, the price had risen to just a tad ove...Read More>>>
Market Cycles Point Towards A Down Week For Stocks
Summary: · The S&P 500 moved higher last week, rising by 0.9%. · Uncertainty in Europe ticked up, as Angela Merkel’s attempt to form a coalition governmen...Read More>>>
Biotech Forum Daily Digest: ASCO Boosts Oncology Concerns. Spotlight On Trevena
"In the land of the blind, the one-eyed man is king." ― Erasmus ...Read More>>>
22 Stocks Moving In Thursday's Pre-Market Session
Gainers Trevena Inc (NASDAQ: TRVN) rose 10.8 percent to $3.60 in pre-market trading after dropping 4.97 percent on Wednesday. Yum China Holdings Inc (NYSE: YUMC) rose 10.2 percent to $31.05 in pre-market trading after the company reported upbe...Read More>>>
Here's Why Trevena Dropped 11.8% Today"
What happened Shares of clinical-stage biopharma Trevena (NASDAQ:TRVN) fell nearly 12% today after it reported full-year 2016 earnings. The pre-revenue company didn't announce any surprises one way or the other. However, investors appear to be consid...Read More>>>